A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Summary: The study aims to compare anti‐obesity interventions in a single evidence synthesis framework. Electronic databases were searched for randomized controlled trials of orlistat, rimonabant or sibutramine reporting weight or body mass index (BMI) change from baseline at 3, 6 or 12 months. A mixed treatment comparison was used to combine direct and indirect trial evidence. Ninety‐four studies involving 24,808 individuals were included; 83 trials included data on weight change and 41 on BMI change. All results are in comparison with placebo. The active drugs were all effective at reducing weight and BMI. At 3 months, orlistat reduced weight by −2.65 kg (95% credibility interval −4.00 kg, −1.31 kg). For sibutramine, 15 mg gave a greater reduction than 10 mg at 12 months, −6.35 kg versus −5.42 kg, respectively. Rimonabant reduced weight by −11.23 kg at 3 months and −4.55 kg at 12 months. Lifestyle advice alone also reduced weight at 6 and 12 months, but was less effective than the pharmacological interventions. In conclusion, modest weight reductions were seen for all pharmacological interventions. Those interventions which have now been withdrawn from use (sibutramine and rimonabant) seem to be the most effective, implying that there may be a place in clinical practice for similar drugs if side effects could be avoided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600 · cited 1×
“Initially, all outcome measures and time points were checked to make sure they formed closed networks (26).”
BackgroundEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“5 times more likely to discontinue the treatment because of depressive mood disorders than were those given placebo and 3 times more likely to discontinue because of anxiety (31).”
BackgroundEvaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 3×
“Abbreviations: BMI, body mass index; CrI, credibility interval; MTC, mixed treatment comparison; OR, odds ratio; SCOUT, Sibutramine Cardiovascular Outcomes trial; T2DM, type 2 diabetes mellitus. obesity reviews (2012) 13, 483–498”
MethodResultInfluentialDirection and impact of language bias in meta-analyses of controlled trials: empirical study
Jüni, P., Holenstein, F., Sterne, J., Bartlett, C., & Egger, M. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.115 · Cited by 892
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · cited 1×
“Orlistat is a lipase inhibitor that reduces the absorption of dietary fat in the gastrointestinal tract (12).”
BackgroundMeta-analysis: The Effect of Dietary Counseling for Weight Loss
Dansinger, M. L., Tatsioni, A., Wong, J. B., Chung, M., & Balk, E. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-1-200707030-00007 · Cited by 467 · cited 1×
“The sensitivity analysis showed that using enhanced advice increased weight loss in the lifestyle group and, contrary to other studies, those with T2DM had a greater weight loss with both active intervention and lifestyle advice at 12 months (30).”
Result
Cited by
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
Owen, R. K., Bradbury, N., Xin, Y., Cooper, N., & Sutton, A. (2019) · Research Synthesis Methods · doi:10.1002/jrsm.1373 · Cited by 427
Self-citationThe Hunger Genes: Pathways to Obesity
van der Klaauw, A. A., & Farooqi, I. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.008 · Cited by 393
Collins, L. M., Dziak, J. J., Kugler, K. C., & Trail, J. B. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.06.021 · Cited by 335
Metadata
- Authors
- Gray, L. J., Cooper, N., Dunkley, A., Warren, F. C., Ara, R., Abrams, K., Davies, M. J., Khunti, K., & Sutton, A.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2012-01-30
- Volume
- 13
- Issue
- 6
- Pages
- 483-498
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2154704030
- Cited by
- 47
- References
- 12
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. https://app.cochat.ai/papers/10.1111/j.1467-789x.2011.00981.x
- The paper
- Gray, L. J., Cooper, N., Dunkley, A., Warren, F. C., Ara, R., Abrams, K., Davies, M. J., Khunti, K., & Sutton, A. (2012). A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obesity Reviews. https://doi.org/10.1111/j.1467-789x.2011.00981.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.